Resources
24 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/29/2024 (updated 4/4/2024)
This session offered a review of the programmatic work of the Foundation for Opioid Response Efforts (FORE), discussed different types of funding opportunities, and then used FORE’s application process as an example of applying for and receiving funding from private foundations.
Posted 3/28/2024 (updated 4/4/2024)
This session outlined how the Communities of Practice for Rural Communities Opioid Response Program (COP-RCORP) Consortium created a Disparities Impact Statement (DIS) that encompassed four Ohio counties (Ashtabula, Fairfield, Sandusky, and Seneca) and three HRSA grants (two RCORP-Psychostimulant grants and one RCORP-Behavioral Health Support grant).
Posted 11/7/2023 (updated 3/28/2024)
Grantees from the Implementation III & IV, Behavioral Health Support, Psychostimulant Support I & II cohorts are invited to this “re-welcome” webinar to kick-off the new project year.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 11/23/2022 (updated 3/27/2024)
This webinar provided RCORP grantees with the tools to complete a disparities impact statement, to support efforts to address populations in rural communities that have historically suffered from poorer health outcomes and health inequities as a part of the prevention, treatment, and recovery of SUD/OUD.
Posted 10/24/2022 (updated 3/27/2024)
During this welcome webinar, FORHP program coordinator and supervisory grants management specialist will review program guidelines and updates, introduce the Technical Assistance and Evaluation Leads from JBS International, and answer initial questions grantees may have to get started with their projects. The RCORP evaluation team will provide an overview of the objectives of the evaluation, the data that will be collected, and resources available to grantees.
Posted 10/24/2022 (updated 3/27/2024)
In this session, we will give an overview of the program, discuss expectations, grant deliverables, and highlight trends in psychostimulant use. We will also discuss the role of the HRSA Project Officer, Grants Management Specialist, Technical Expert Leads, and Evaluation Team.